ADTX Stock Overview
A biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aditxt, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$380.00 |
| 52 Week Low | US$0.31 |
| Beta | 1.08 |
| 11 Month Change | -63.16% |
| 3 Month Change | -99.06% |
| 1 Year Change | -99.77% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Aditxt gains on regaining compliance with Nasdaq listing requirements
Sep 29Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split
Sep 13Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate
Jul 08Aditxt adds Lauren Chung to board of directors
Jun 18Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring
Dec 14We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth
Nov 23
Shareholder Returns
| ADTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.9% | -3.7% | 0.3% |
| 1Y | -99.8% | 15.2% | 31.1% |
Return vs Industry: ADTX underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: ADTX underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| ADTX volatility | |
|---|---|
| ADTX Average Weekly Movement | 22.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADTX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 47 | Amro Albanna | www.aditxt.com |
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis.
Aditxt, Inc. Fundamentals Summary
| ADTX fundamental statistics | |
|---|---|
| Market cap | US$2.84m |
| Earnings (TTM) | -US$40.76m |
| Revenue (TTM) | US$212.11k |
14.0x
P/S Ratio-0.1x
P/E RatioIs ADTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADTX income statement (TTM) | |
|---|---|
| Revenue | US$212.11k |
| Cost of Revenue | US$842.34k |
| Gross Profit | -US$630.23k |
| Other Expenses | US$40.13m |
| Earnings | -US$40.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.66 |
| Gross Margin | -297.13% |
| Net Profit Margin | -19,217.17% |
| Debt/Equity Ratio | 202.0% |
How did ADTX perform over the long term?
See historical performance and comparison